Intra-arterial chemotherapy for retinoblastoma treatment in Chile: Experience and results 2013–2020

Oporto, Joaquín I.; Zúñiga, P.; Ossandón, D.; Zanolli, Mario; Pérez, Verónica; López, Juan Pablo; Stetcher, X.; Rodriguez, Anabel; Puentes, Ángel; Rustom, S.; Lobos, José María

doi:10.1016/j.oftale.2020.10.003

Cited by 8 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, it has been adopted as primary and salvage therapy for both unilateral and bilateral retinoblastoma worldwide and is performed in more than 45 countries. Every series published to date, from the US, China, India, Argentina, Italy, Switzerland, Malaysia, and others, has concluded that the technique is better, safer, and more effective (33)(34)(35)(36)(37)(38)(39).…”

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

et al. 2022

View full text Add to dashboard Cite

The management of retinoblastoma, the most common intraocular malignancy in children, has changed drastically over the last decade. Landmark developments in local drug delivery, namely, safer techniques for intravitreal chemotherapy injection and ophthalmic artery chemosurgery, have resulted in eye globe salvages that were not previously attainable using systemic chemotherapy or external beam irradiation. Novel drugs, oncolytic viruses, and immunotherapy are promising approaches in the treatment of intraocular retinoblastoma. Importantly, emerging studies of the pattern of tumor dissemination and local drug delivery may provide the first steps toward new treatments for metastatic disease. Here, we review recent advances in retinoblastoma treatment, especially with regard to local drug delivery, that have enabled successful conservative management of intraocular retinoblastoma. We also review emerging data from preclinical and clinical studies on innovative approaches that promise to lead to further improvement in outcomes, namely, the mechanisms and potential uses of new and repurposed drugs and non-chemotherapy treatments, and discuss future directions for therapeutic development.

show abstract

Section: Ophthalmic Artery Chemosurgerymentioning

confidence: 99%

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In Latin America, OAC was first introduced by the Argentinian group after training in New York in 2009 as a result of a long-term collaboration 10,15 . However, as opposed to the North American experience, in Argentina (and later in other Latin American countries), OAC was mostly used for the treatment of relapsed or advanced bilateral disease and less frequently for patients with unilateral disease 9,10 . Later, this treatment was gradually introduced in other countries included in this consensus document 9,11,16 .…”

Section: Intra-arterial Chemotherapymentioning

confidence: 99%

“…As opposed to other pediatric malignancies, these outstanding results were not achieved by international cooperative groups performing prospective studies. Therefore, most referral centers for retinoblastoma in South America also moved from systemic to ocular delivery of chemotherapy for the conservative treatment resulting in unprecedented ocular salvage rates and near total elimination of EBRT [9][10][11] . This document is the result of a consensus of the current management in institutions participating in the GALOP group, which included collaborating institutions in Spain and Portugal.…”

Section: Introductionmentioning

confidence: 99%

How We Approach Conservative Treatment of Retinoblastoma in South America in the Era of Local Ocular Treatments. A Consensus of the Grupo America Latina De Oncologia Pediatrica (Galop)

Lopez

Sampor

Grigorovski

et al. 2022

Preprint

View full text Add to dashboard Cite

Local therapies replaced systemic chemotherapy for ocular preservation in retinoblastoma. In middle income countries, these techniques pose specific challenges mostly related to more advanced disease at diagnosis. The Grupo de America Latina de Oncologia Pediatrica (GALOP developed a consensus document for the management of conservative therapy for retinoblastoma. Intra-arterial chemotherapy (OAC) is the preferred therapy, except those with less advanced disease or age younger than 6 months. OAC allowed for the elimination of the use of external beam radiotherapy in our setting. Intravitreal chemotherapy is the preferred treatment for vitreous seeding. Enucleation is the treatment of choice for advanced eyes.

show abstract

“…The results of this treatment in eyes with vitreous or subretinal seeding were modest; therefore, several major institutions in high‐income countries have implemented ocular chemotherapy techniques such as ophthalmic artery intra‐arterial (OAC) and intra‐vitreal chemotherapy in order to allow greater delivery of chemotherapy to the eye with fewer systemic effects 8 . Most referral centers for retinoblastoma in South America also moved from systemic to ocular delivery of chemotherapy for conservative treatment, resulting in increased ocular salvage rates and near‐total elimination of EBRT 9–11 . Despite there is a relative paucity of evidence coming from prospective studies in retinoblastoma, the participants of this group elaborated this consensus report on the current management of retinoblastoma at institutions participating in the GALOP group, which also included collaborating institutions in Spain and Portugal.…”

Section: Introductionmentioning

confidence: 99%

How we approach conservative treatment of retinoblastoma in South America in the era of local ocular treatments: A consensus of the Grupo America Latina de Oncologia Pediatrica (GALOP)

Garin

Sampor

Grigorovski

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Local therapies are increasingly used for ocular preservation in retinoblastoma. In middle‐income countries, these techniques pose specific challenges mostly related to more advanced disease at diagnosis. The Grupo de America Latina de Oncología Pediátrica (GALOP) developed a consensus document for the management of conservative therapy for retinoblastoma. Intra‐arterial chemotherapy (OAC) is the preferred therapy, except for those with less advanced disease or age younger than 6 months. OAC allowed for a reduction in the use of external beam radiotherapy in our setting. Intravitreal chemotherapy is the preferred treatment for vitreous seeding. Enucleation is the treatment of choice for eyes with advanced disease.

show abstract

Intra-arterial chemotherapy for retinoblastoma treatment in Chile: Experience and results 2013–2020

Cited by 8 publications

References 21 publications

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

Treatment of Retinoblastoma: What Is the Latest and What Is the Future

How We Approach Conservative Treatment of Retinoblastoma in South America in the Era of Local Ocular Treatments. A Consensus of the Grupo America Latina De Oncologia Pediatrica (Galop)

How we approach conservative treatment of retinoblastoma in South America in the era of local ocular treatments: A consensus of the Grupo America Latina de Oncologia Pediatrica (GALOP)

Contact Info

Product

Resources

About